This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • Growth Hormone Deficiency
  • /
  • BSPED recommendations for the use of once-weekly L...
Guideline

BSPED recommendations for the use of once-weekly LAGH therapy in children with GHD

Read time: 1 mins
Last updated: 1st Oct 2025
Availability: Free full text
Status: Current
Recommendations for the use of once-weekly long-acting growth hormone therapy in children with growth hormone deficiency - British Society for Paediatric Endocrinology and Diabetes (BSPED)


Long-acting growth hormone (LAGH) is now available in the UK and is recommended by NICE (2023) as an option for the treatment of growth hormone deficiency (GHD) for children and young people aged three years and over.

Currently two LAGH preparations are approved by NICE (somatrogon and somapacitan). This guidance focuses on these two preparations and will be updated when new LAGH preparations are accessible to patients in the UK. A “quick reference guide” is provided on pages 6-7, but we recommend reading the full guideline to understand the basis behind the recommendations in that table.

International consensus guidelines on the use of LAGH in children with GHD are also available and include somatrogon, somapacitan and lonapegsomatropin.


Read full Guideline